Sale is live|00:00:00

Sudarshan Chemical Industries Ltd Q1 FY27 Earnings Analysis

Published 11 Jun 2026 | Chemicals & Petrochemicals | Market Cap: ₹7.2K Cr

Price

857

Market Cap

₹7.2K Cr

P/E Ratio

1959.9

Revenue Rank

Rank 4

Margin Rank

Rank 3

Earnings Summary

- The pigment industry has seen a global growth of 3-4% over the last 2-3 years, generally aligned with GDP growth. - Entering FY27 with a stronger platform and clear execution agenda aiming for sustainable profitability.

📊 Revenue & Sales Performance

Rank 4

- The pigment industry has seen a global growth of 3-4% over the last 2-3 years, generally aligned with GDP growth. - Sudarshan Chemical expects 8-10% volume growth in its legacy business for FY27. - Q4 showed a strong volume-led recovery with customers starting to buy again after destocking. - Integration of acquisitions and value capture initiatives are expected to drive EBITDA growth targeted at EUR 35 million for FY27. - The company anticipates no immediate capacity constraints, with sufficient headroom in both legacy and acquired plants for volume growth. - Demand outlook is cautiously optimistic despite geopolitical uncertainties; paint and housing markets (especially in the U.S.) expected to recover, supporting future demand. - Winning back market share and customer trust is a key factor in growth beyond industry averages. - Inventory normalization and improved supply chain alignment are expected to support sustainable sales growth.

📈 Profitability & Margins

Rank 3

- Entering FY27 with a stronger platform and clear execution agenda aiming for sustainable profitability. - Expecting 8% to 10% volume growth on the legacy business in FY27. - Business EBITDA target of EUR 35 million for next financial year, driven by synergies, value capture, and sales growth. - EBITDA improvements expected over next 3-4 years, targeting EUR 90-100 million from integration benefits. - Confident of maintaining healthy margins despite raw material and energy cost inflation by passing on costs to customers. - Capacity headroom sufficient in both legacy and acquired businesses, no immediate capex required for volume growth. - Positive trajectory supported by volume recovery, margin discipline, and cost optimization. - Continuous improvement expected in turnaround businesses like RIECO over coming years. - Net debt reduction indicates healthier balance sheet supporting profitable growth.

🏗️ Capital Expenditure Plans

No

- No specific current or future capex figures mentioned; however, the company states that for the projected 3-4 years of growth (EBITDA targets), no additional volume-related capex investment is required as there is enough capacity headroom in both legacy and acquired businesses. - The company has completed expansions in the Indian plant and has debottlenecking capacity left for growth. - Integration initiatives such as the One SAP Drive project (Integra) to integrate systems are underway, expected completion by year-end, which is a strategic IT investment. - The setting up of a Global Capability Center (GCC) has been initiated to improve operational efficiency. - Exploration of non-core asset disposals is underway as part of supply chain realignment, but no definitive capex plans related to this. - Overall, focus is on value capture initiatives and integration rather than large-scale new capital expenditures.

💰 Fundraising & Capital Structure

No information

- No explicit mention of new fundraising through debt or equity in the call transcript. - Current net debt at group level is around INR 755-760 crores, similar to pre-acquisition levels. - Debt repayment schedule is ballooning, with repayments starting in the current financial year and stepping up gradually. - Management is confident that EBITDA growth will support debt repayment over the next 4-5 years. - Cash is mostly held in the Indian entity, with operations cash flow expected to service debt in acquired group. - Focus appears to be on reducing existing debt from acquisition finance rather than raising new funds. - No direct indication of planned equity fundraising or new debt issuance was discussed.

📋 Order Book & Pipeline

No information

The transcript provided in the Sudarshan Chemical Industries Limited Q4 and FY26 earnings call does not explicitly mention the current or expected order book or pending orders. However, key relevant points related to demand and business outlook include: - Q4 showed strong volume recovery, driven by customers starting to buy after destocking. - Demand is currently muted, with customers cautious about inventory buildup due to geopolitical uncertainties. - Industry growth generally aligns with GDP, averaging 3%-4% globally. - Sudarshan is winning back customers and improving supply chain alignment, contributing to growth beyond just industry expansion. - The company expects volume recovery and steady growth going forward, with EBITDA improvements expected over the next 3-4 years. - Inventory rationalization is ongoing, targeting normalized inventory levels over the next year. No specific value or size of order book or pending orders was discussed in the call excerpts provided.

Key Metrics

Revenue

Rank 4

Margin

Rank 3

Capex

No

Fundraise

No information

Order Book

No information

Frequently Asked Questions

What were Sudarshan Chemical Industries Ltd Q1 FY27 results?

- The pigment industry has seen a global growth of 3-4% over the last 2-3 years, generally aligned with GDP growth. - Entering FY27 with a stronger platform and clear execution agenda aiming for sustainable profitability.

What is Sudarshan Chemical Industries Ltd share price analysis?

Sudarshan Chemical Industries Ltd currently shows a neutral. The stock trades at a P/E of 1959.9 with a market cap of ₹7,189. Investors should review the full earnings analysis for detailed insights.

Is Sudarshan Chemical Industries Ltd planning capital expenditure?

- No specific current or future capex figures mentioned; however, the company states that for the projected 3-4 years of growth (EBITDA targets), no additional volume-related capex investment is required as there is enough capacity headroom in both legacy and acquired businesses.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.